Trial NCT02787304

View at ClinicalTrials.gov 
Org. Study IDs: SHP626-201
Secondary IDs: 2016-000203-82

Last trial update was posted on 2019-11-25

MeSH Interventions

Volixibat

MeSH Conditions

Fatty Liver Non-alcoholic Fatty Liver Disease

Other Conditions

Non-Alcoholic Steatohepatitis

Stopping Reasons

N/A

Limitations And Caveats

At the Week 24 Interim Analysis, no differences were observed between any dose of Volixibat and placebo based on absolute change in steatosis from baseline, as assessed by MRI hepatic PDFF, and % change from baseline in ALT; the study was terminated.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID